WWM
XENE icon

Whalen Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

Whalen Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,641
Closed -$208K – 232
2025
Q4 		$208K Buy
+4,641
New +$195K 0.11% 186

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Whalen Wealth Management's XENE Position: Q1 2026 in Review

Whalen Wealth Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 4,641 shares — an estimated $208K sold.

Whalen Wealth Management first reported a position in XENE in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Whalen Wealth Management reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Whalen Wealth Management sold 4,641 Xenon Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • Whalen Wealth Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Whalen Wealth Management's Xenon Pharmaceuticals position peaked at $208K in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Whalen Wealth Management's 13F filing for Q1 2026, filed 13 Apr 2026.